# Chroma Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chroma-therapeutics

- Industry: Biotechnology
- Headquarters: Abingdon, UK
- Website: www.chromatherapeutics.com
- Total disclosed funding: $103M
- Latest round: Series D (Jun 19, 2009)
- Investors on record: 6

## About

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches.

## Funding rounds

- Series D, Jun 19, 2009, $25M — Abingworth, Essex Woodlands, Wellcome Trust, Gilde Healthcare, Phase4 Partners, GlaxoSmithKline
- Series C, Mar 21, 2006, $52M — Abingworth, Essex Woodlands, Wellcome Trust, Gilde Healthcare, Phase4 Partners
- Series B, May 20, 2004, $26M — Abingworth, Wellcome Trust, Gilde Healthcare

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B, Series C, Series D
- Wellcome Trust — Series B, Series C, Series D
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series B, Series C, Series D
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series C, Series D
- Phase4 Partners (https://capitalatlas.ai/funds/phase4-partners) — Series C, Series D
- GlaxoSmithKline — Series D